One major function of the liver is the uptake of endo- and xenobiotics from the bloodstream and their excretion into bile. The transport systems involved in hepatobiliary transport have been recently cloned and characterized at the molecular level and it is becoming clear that mutations and polymorphisms of individual transporter molecules underlie a variety of liver diseases. Furthermore, new research has shown that bile acids, whose function in digestion is long known, also behave as signal molecules in a variety of organs, including the intestinal and biliary epithelia, sinusoidal endothelial and immune cells. This book provides indepth surveys on the structure and function of transport molecules involved in hepatobiliary transport, on the role of different bile acids receptors in various organs and their function in health and disease, the mechanisms of bile salt-induced apoptosis and hepatocyte protection, and the role of transporter mutations as causes and modifiers of liver diseases. The book will be of interest not only for biochemists, structural chemists and biologists, but also for clinicians.
Inhaltsverzeichnis
1;Preface;5 2;List of Contributors;7 3;Abbreviations;17 4;1 Physiology of bile formation: Hepatocellular bile salt transporters;21 4.1;1.1 Introduction;21 4.2;1.2 Sodium-dependent bile salt uptake into hepatocytes;23 4.3;1.3 Sodium-independent bile salt uptake into hepatocytes;27 4.4;1.4 Bile salt export across the canalicular membrane;28 4.5;1.5 Bile salt salvage systems;32 4.6;1.6 Concluding remarks;32 4.7;1.7 References;33 5;2 Structure and function of hepatic ABC transporters;43 5.1;2.1 Introduction to human ABC transporters expressed in the liver;43 5.2;2.2 Structure and function of the bile salt export pump (ABCB11; BSEP);45 5.3;2.3 Structure and function of the multidrug resistance protein 3 (ABCB4; MDR3);52 5.4;2.4 Structure and function of the breast cancer resistance protein (ABCG2; BCRP);57 5.5;2.5 Concluding remarks;60 5.6;2.6 References;61 6;3 Short- and long-term regulation of hepatobiliary transport;69 6.1;3.1 Introduction;69 6.2;3.2 Short-term regulation of sinusoidal transport systems;69 6.3;3.3 Long-term regulation of sinusoidal transport systems;71 6.4;3.4 Short-term regulation of canalicular secretion;74 6.5;3.5 Long-term regulation of canalicular transport systems;76 6.6;3.6 Methods of studying subcellular transporter distribution;78 6.7;3.7 Summary;79 6.8;3.8 References;80 7;4 Nuclear bile acid receptor FXR and hepatobiliary transport systems;91 7.1;4.1 Introduction;91 7.2;4.2 Nuclear receptors;91 7.3;4.3 Bile acids and the enterohepatic circulation;94 7.4;4.4 Bile acid homeostasis, enterohepatic circulation, and FXR;95 7.5;4.5 The role of FXR in the pathogenesis of biliary diseases;99 7.6;4.6 Concluding remarks;100 7.7;4.7 References;101 8;5 Bile acid signaling in the liver and the biliary tree;105 8.1;5.1 Introduction;105 8.2;5.2 Bile acid signaling in liver parenchymal cells (hepatocytes);105 8.3;5.3 Bile acid signaling in sinusoidal endothelial cells;109 8.4;5.4 Bile acid signaling in Kupffer cells;110 8.5;5.5 Bile acid signaling in hepatic
stellate cells;111 8.6;5.6 Bile acid signaling in the biliary tree;113 8.7;5.7 References;116 9;6 Modulation of innate immunity and inflammation by bile acids and their receptors;123 9.1;6.1 Introduction;123 9.2;6.2 Impact of FXR deletion on immunity and inflammation - lessons from FXR knockout mice;126 9.3;6.3 Role of TGR5 in the modulation of immune function;128 9.4;6.4 Effects of bile acids on immunological function independently of bile acid receptors;129 9.5;6.5 Obstructive jaundice and its impact on immune function;130 9.6;6.6 Role of bile acids and FXR in viral infections;131 9.7;6.7 Concluding remarks;131 9.8;6.8 References;132 10;7 Bile acids as extrahepatic and interorgan signaling molecules;137 10.1;7.1 Introduction;137 10.2;7.2 Bile acid-dependent modulation of glucose homeostasis;138 10.3;7.3 Impact of bile acids on energy expenditure;140 10.4;7.4 Bile acid receptors and immune response;140 10.5;7.5 Role of bile acid receptors in the cardiovascular system;141 10.6;7.6 Role of bile acid receptors in the kidney;142 10.7;7.7 Bile acid receptors in the central and peripheral nervous system;144 10.8;7.8 Summary and future perspectives;144 10.9;7.9 References;145 11;8 Disorders of bile duct development;151 11.1;8.1 Introduction;151 11.2;8.2 Morphogenesis of the intrahepatic bile duct epithelium: molecular players involved and their relationship with arterial morphogenesis;151 11.3;8.3 Ductal plate malformation (DPM): definition, clinical heterogeneity, and classification based on animal models;156 11.4;8.4 Cilia in cholangiocytes: a multifunctional transducing system;156 11.5;8.5 DPM-related cholangiopathies;158 11.6;8.6 Alagille's syndrome (AGS);165 11.7;8.7 References;166 12;9 Mutations of the bile salt export pump (BSEP) and multidrug-resistance protein 3 (MDR3);171 12.1;9.1 Introduction;171 12.2;9.2 BSEP-related liver diseases;171 12.3;9.3 MDR3-related liver diseases;178 12.4;9.4 Treatment of BSEP- and MDR3-associated liver diseases;182 12.5;9.5 Concludi
ng remarks;182 12.6;9.6 References;183 13;10 MRP2 (ABCC2) and disorders of bilirubin handling in liver;191 13.1;10.1 Introduction;191 13.2;10.2 The conjugate efflux pump MRP2 in the hepatocyte canalicular membrane;191 13.3;10.3 Formation of unconjugated bilirubin and its uptake into hepatocytes;193 13.4;10.4 Formation of bilirubin glucuronides and their transport into bile by MRP2;194 13.5;10.5 Uptake of bilirubin glucuronides into hepatocytes;194 13.6;10.6 MRP3, a basolateral efflux pump, contributes to conjugated hyperbilirubinemia;195 13.7;10.7 Genetic disorders and drug-induced inhibition of bilirubin uptake into hepatocytes;195 13.8;10.8 Genetic variants of the MRP2 (ABCC2) gene and MRP2 deficiency in Dubin-Johnson syndrome;196 13.9;10.9 Impairment of MRP2 localization in the hepatocyte canalicular membrane;197 13.10;10.10 References;197 14;11 Hepatobiliary transport during pregnancy: Cross talk between transporters and hormones;203 14.1;11.1 Introduction;203 14.2;11.2 Estrogens as cholestatic agents;203 14.3;11.3 Cholestatic activity of progesterone;205 14.4;11.4 Biochemical observations in symptom-free pregnant women;206 14.5;11.5 Genetic lessons from congenital cholestasis;206 14.6;11.6 Transporter variants and cholestasis of pregnancy;207 14.7;11.7 Nuclear receptors and cholestasis of pregnancy;209 14.8;11.8 Gallstones and pregnancy;209 14.9;11.9 Concluding remarks;210 14.10;11.10 References;210 15;12 Hepatobiliary transport and gallstone formation;215 15.1;12.1 Introduction;215 15.2;12.2 Epidemiology and risk factors of cholelithiasis;215 15.3;12.3 Hepatobiliary transporters and the pathophysiology of gallstone formation;216 15.4;12.4 Genetic variation in hepatobiliary transporter genes and gallstone susceptibility;219 15.5;12.5 Concluding remarks;222 15.6;12.6 References;223 16;13 Molecular basis of primary biliary cirrhosis;227 16.1;13.1 Introduction;227 16.2;13.2 Pathogenesis of PBC;230 16.3;13.3 Concluding remarks;234 16.4;13.4 References;235 17;14 The
molecular basis of primary sclerosing cholangitis;243 17.1;14.1 Introduction;243 17.2;14.2 Immune-mediated bile duct injury;247 17.3;14.3 Toxic bile duct injury;251 17.4;14.4 Fibrosis and cirrhosis;252 17.5;14.5 Cancer development;253 17.6;14.6 Concluding remarks;253 17.7;14.7 References;255 18;15 Drug-induced cholestatic liver injury;261 18.1;15.1 Introduction;261 18.2;15.2 Diagnostic criteria of drug-induced cholestasis;261 18.3;15.3 Hepatocellular drug concentration;262 18.4;15.4 Hepatic bile salt accumulation;264 18.5;15.5 Susceptibility to drug-induced cholestasis;265 18.6;15.6 Concluding remarks;267 18.7;15.7 References;267 19;16 Bile acids and receptors: Therapeutic relevance;273 19.1;16.1 Introduction;273 19.2;16.2 Nuclear and membrane BA receptors: general concepts;273 19.3;16.3 Therapeutic potential of BAs;274 19.4;16.4 Role of BA receptors in BA homeostasis and bile production: therapeutic implications in cholestasis;274 19.5;16.5 Role of BA receptors for targeting hepatic inflammation and fibrosis;277 19.6;16.6 Role of BA receptors in the pathogenesis and treatment of gallstone disease;278 19.7;16.7 BA receptors in intestine: therapeutic implications for the gut-liver axis and inflammatory bowel disease;279 19.8;16.8 Role of BAs in lipid metabolism: therapeutic implications for atherosclerosis and nonalcoholic fatty liver disease (NAFLD);280 19.9;16.9 Role of BAs in hepatic glucose metabolism and beyond;282 19.10;16.10 BA receptors in hepatobiliary and colorectal cancer;284 19.11;16.11 BA receptors beyond the liver and gastrointestinal tract;285 19.12;16.12 Concluding remarks;285 19.13;16.13 References;286 20;17 Analysis of bile acids by tandem mass spectrometry;297 20.1;17.1 Introduction;297 20.2;17.2 Experimental procedures;298 20.3;17.3 Applications;301 20.4;17.4 Summary;306 20.5;17.5 References;307 21;Index;309